These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6327190)

  • 21. [Veralipride and menopause].
    Laffargue F; Viala JL; Durand G
    Sem Hop; 1983 Sep; 59(29-30):2127-30. PubMed ID: 6312585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.
    Prior JC; Nielsen JD; Hitchcock CL; Williams LA; Vigna YM; Dean CB
    Clin Sci (Lond); 2007 May; 112(10):517-25. PubMed ID: 17419685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy and clinical and biological tolerability of the long-term administration of veralipride. Apropos of 74 cases].
    Dargent D; Dumont M; Malinas Y
    Sem Hop; 1983 Nov; 59(40):2778-80. PubMed ID: 6316535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A new therapeutic approach to menopausal sudden flushes and psychofunctional disorders (author's transl)].
    Quereux C; Ezes H; Deltour G; Decaux J; Dorangeon P; Wahl P
    Sem Hop; 1980 Oct; 56(37-38):1453-9. PubMed ID: 6254160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical use of a preparation based on phyto-oestrogens in the treatment of menopausal disorders.
    Russo R; Corosu R
    Acta Biomed; 2003 Dec; 74(3):137-43. PubMed ID: 15055018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.
    Vercellini P; Vendola N; Colombo A; Passadore C; Trespidi L; Crosignani PG
    Gynecol Obstet Invest; 1992; 34(2):102-4. PubMed ID: 1398260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of conjugated equine oestrogens with and without the addition of cyclical medrogestone on hot flushes, liver function, blood pressure and endocrinological indices.
    Sonnendecker EW; Polakow ES
    S Afr Med J; 1990 Mar; 77(6):281-5. PubMed ID: 2156343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms.
    Place VA; Powers M; Darley PE; Schenkel L; Good WR
    Am J Obstet Gynecol; 1985 Aug; 152(8):1092-9. PubMed ID: 2992278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
    Cieraad D; Conradt C; Jesinger D; Bakowski M
    Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oestrogens and menopausal and postmenopausal women.
    Hailes J; Burger H
    Med J Aust; 1977 May; 1(22):803-6. PubMed ID: 196165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and hormonal effects of long-term veralipride treatment in post-menopausal women.
    Verbeke K; Dhont M; Vandekerckhove D
    Maturitas; 1988 Oct; 10(3):225-30. PubMed ID: 3185294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of different dopamine agonists and antagonists on post-menopausal hot flushes.
    Zichella L; Falaschi P; Fioretti P; Melis GB; Cagnacci A; Gambacciani M; Mancini S
    Maturitas; 1986 Oct; 8(3):229-37. PubMed ID: 3784919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of oestrogen replacement in the climacteric syndrome.
    Strickler RC; Borth R; Cecutti A; Cookson BA; Harper JA; Potvin R; Riffel P; Sorbara VJ; Woolever CA
    Psychol Med; 1977 Nov; 7(4):631-9. PubMed ID: 201958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Actual status of veralipride use.
    Carranza-Lira S
    Clin Interv Aging; 2010 Sep; 5():271-6. PubMed ID: 20852674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
    Chakravarti S; Collins WP; Thom MH; Studd JW
    Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Climacteric syndrome: comparison of several secondary therapies].
    Bianco V; Colombo A; Tassan Simonat P
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):54-60. PubMed ID: 1929099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases].
    Masmoudi K; Gras-Champel V; Lemaire-Hurtel AS; Masson H; Munier A; Geslin JM; Andréjak M
    Rev Med Interne; 2005 Jun; 26(6):453-7. PubMed ID: 15936474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women.
    Yu H; Racketa J; Chines AA; Mirkin S
    Climacteric; 2013 Apr; 16(2):252-7. PubMed ID: 23035721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. alpha-Methyldopa for climacteric hot flushes. A double-blind, randomized, cross-over study.
    Andersen O; Engebretsen T; Solberg VM; Orbo A
    Acta Obstet Gynecol Scand; 1986; 65(5):405-9. PubMed ID: 3535358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.